Amgen Inc. (AMGN)
| Market Cap | 141.58B |
| Revenue (ttm) | 32.53B |
| Net Income (ttm) | 4.23B |
| Shares Out | 537.53M |
| EPS (ttm) | 7.83 |
| PE Ratio | 33.62 |
| Forward PE | 12.75 |
| Dividend | $9.52 (3.62%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 13,367,837 |
| Open | 269.00 |
| Previous Close | 261.19 |
| Day's Range | 262.21 - 269.61 |
| 52-Week Range | 253.30 - 346.85 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 329.05 (+24.93%) |
| Earnings Date | Feb 4, 2025 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; N... [Read more]
Financial Performance
In 2023, Amgen's revenue was $28.19 billion, an increase of 7.09% compared to the previous year's $26.32 billion. Earnings were $6.72 billion, an increase of 2.52%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $329.05, which is an increase of 24.93% from the latest price.
News
What's Going On With Amgen Stock On Friday?
On Friday, Novo Nordisk A/S NVO released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program.
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
LONDON--(BUSINESS WIRE)---- $AMGN #biotech--PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQ: SLXN). The precision oncology sector has rapidly evolved into one of the mo...
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "M...
AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND
THOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025.
BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding ...
Healthy Returns: Wall Street mulls over Amgen's weight loss drug data
Wall Street is chewing over data on Amgen's weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese drug company.
Amgen to invest $1 bln in North Carolina manufacturing site
U.S. drugmaker Amgen said on Thursday it will invest $1 billion towards a second drug substance manufacturing facility in North Carolina.
AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA
Investment Establishes Second Facility in Holly Springs; Builds on Previous $550M Commitment THOUSAND OAKS, Calif. , Dec. 5, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $1 billion expa...
Dow 30 December Dogs Show 28 Pay Dividends And 1 "Safer" Buy
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding its single share price. Five more Dow Dogs, including Cisco and Merck, are within 66% of meeting this idea...
Amgen Inc. (AMGN) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 10:00 AM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer J...
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's AMGN new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight...
Bargain Hunting In A Pricey Market: 2 High-Yield Dividend Picks That Have Me Hooked
With markets surging, finding high-yield bargains can feel impossible. Yet, opportunities still exist for disciplined, value-focused investors. My strategy targets strong, dividend-paying businesses t...
AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m.
AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE
THOUSAND OAKS, Calif. , Nov. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m.
Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You
Amgen's MariTide shows up to 20% weight loss in Phase II, leaving room for improvement beyond 52 weeks, as weight loss did not plateau. GI side effects are a concern, but Amgen plans to address them t...
Where to invest in GLP-1 stocks
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Squawk on the Street' to discuss Amgen's mid-stage trial results for its experimental obesity drug, why she remains bullish on the comp...
Final Trade: JWN, IWM, GCO, AMGN
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond
Piper Sandler's Christopher Raymond joins 'Fast Money' to talk Amgen's stock sinking on GLP-1 results.
Stock Market Today: The S&P 500 Reclaims the 6K Level
Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.
Amgen: MariTide Underwhelms, But There Are Ways To Win
Shares of Amgen fell after the company reported underwhelming phase 2 data with weight loss up to 20% in obese patients after 52 weeks of treatment. The results underperformed Street expectations. I b...
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
Amgen (AMGN) shares tanked Tuesday after results from a test of the biotech's experimental weight-loss drug came in below expectations.
Chart of the Day: Amgen
Amgen on pace for its worst day since October of 2000. It's our Chart of the Day.
S&P, Nasdaq climb while Dow dips amid Trump tariff concerns; Amgen, Kohl's shares tumble
The S&P 500 and Nasdaq Composite rose on Tuesday, while Dow Jones slipped as investors assessed the threat of new tariffs from President-elect Donald Trump. The S&P 500 index rose 0.2%, while the Nas...
Cramer's Stop Trading: Amgen
CNBC's Jim Cramer explains why he is keeping an eye on shares of Amgen.